Mumme Achim, Heinen Wilfried, Geier Bruno, Maatz Winfried, Barbera Letterio, Walterbusch Gerhard
Division of Vascular Surgery, St Josef-Hospital, Ruhr-University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany.
J Vasc Surg. 2002 Dec;36(6):1219-24. doi: 10.1067/mva.2002.128296.
Because of the dose-dependent increase in bleeding complications, the intraoperative administration of fibrinolytic agents is limited. This limitation impairs the efficacy of fibrinolytic therapy because low-dose fibrinolysis often fails in the treatment of complex deep venous thrombosis (DVT). The aim of this study was to investigate the efficacy and safety of intraoperative high-dose fibrinolytic therapy for extended DVT, which was performed with the regional hyperthermic fibrinolytic perfusion (RHFP) technique.
From January 1993 to June 2001, in 53 patients with extended DVT, unsuccessful venous thrombectomy (recanalization, <50%) was followed by RHFP with 0.5 mg/kg of body weight of recombinant tissue plasminogen activator. The extent of thrombosis was documented before, during (after the surgical thrombectomy), and after (between postoperative days 2 and 5) surgery with phlebography and was quantified with the Marder score. Intraoperative and postoperative complications were recorded prospectively.
After RHFP, a recanalization was achieved in 64 of 146 venous segments (43.8%) that were still occluded despite thrombectomy. Eighty-two segments (56.2%) remained occluded. Compared with the preoperative phlebography, 32 patients (60.3%) had a successful recanalization (>50%). Eleven patients (20.8%) showed minimal and 10 patients (18.9%) no recanalization. No lethal complications occurred. One patient (1.9%) had pulmonary embolism develop, and two patients (3.8%) had bleeding complications develop.
With the intraoperative use of hyperthermia-assisted high-dose fibrinolysis, improvement of the results of mechanical thrombectomy of extended DVT was possible. The RHFP protected against systemic side effects of the fibrinolysis and show a high safety of application.
由于出血并发症呈剂量依赖性增加,纤维蛋白溶解剂的术中应用受到限制。这种限制损害了纤维蛋白溶解疗法的疗效,因为低剂量纤维蛋白溶解常常无法有效治疗复杂的深静脉血栓形成(DVT)。本研究的目的是探讨采用区域热纤维蛋白溶解灌注(RHFP)技术进行术中高剂量纤维蛋白溶解疗法治疗广泛性DVT的疗效和安全性。
1993年1月至2001年6月,53例广泛性DVT患者在行静脉血栓切除术未成功(再通率<50%)后,采用每千克体重0.5mg重组组织型纤溶酶原激活剂进行RHFP治疗。在手术前、手术中(手术血栓切除术后)和手术后(术后第2至5天之间),通过静脉造影记录血栓形成的范围,并用Marder评分进行量化。前瞻性记录术中及术后并发症。
RHFP治疗后,146个尽管已行血栓切除术仍闭塞的静脉节段中有64个(43.8%)实现再通。82个节段(56.2%)仍闭塞。与术前静脉造影相比,32例患者(60.3%)实现了成功再通(>50%)。11例患者(20.8%)再通程度极小,10例患者(18.9%)未实现再通。未发生致命并发症。1例患者(1.9%)发生肺栓塞,2例患者(3.8%)发生出血并发症。
术中使用热辅助高剂量纤维蛋白溶解疗法可改善广泛性DVT机械性血栓切除术的效果。RHFP可防止纤维蛋白溶解的全身副作用,且显示出较高的应用安全性。